Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
Purified decay-accelerating factor (DAF), from the stroma of normal human erythrocytes, was incorporated into the membranes of erythrocytes of patients with paroxysmal nocturnal hemoglobinuria (PNH), and its effect on the complement sensitivity of the cells was investigated. Reconstitution with exogenous DAF restored the ability of the affected PNH cells to resist assembly of the homologous C3 convertase, C4b2a, on their surfaces, and decreased the susceptibility of the cells to lysis in acidified serum. Conversely, treatment of normal erythrocytes with monoclonal or polyclonal anti-DAF antibodies abrogated the capacity of the normal cells to circumvent C4b2a assembly and rendered the cells sensitive to acid lysis. These findings show that the previously reported association of DAF deficiency with PNH is causally related to the lytic abnormalities of the cells and clarify the molecular basis for restriction of autologous convertase formation on normal human erythrocytes.
Medof
M E
ME
Kinoshita
T
T
Silber
R
R
Nussenzweig
V
V
D000143:Acids; D001798:Blood Proteins / Q000276:immunology*; D018958:CD55 Antigens; D050577:Complement C3-C5 Convertases / Q000097:blood; D003171:Complement Pathway, Classical; D004912:Erythrocytes / Q000276:immunology; D006457:Hemoglobinuria, Paroxysmal / Q000097:blood / Q000276:immunology*; D006461:Hemolysis; D006801:Humans; D066298:In Vitro Techniques; D011951:Receptors, Complement / Q000276:immunology
D000143:Acids; D001798:Blood Proteins; D018958:CD55 Antigens; D011951:Receptors, Complement; D050577:Complement C3-C5 Convertases